Mechanism of action of fluoropyrimidines: Relevance to the new developments in colorectal cancer chemotherapy

Seminars in Oncology

Volumn 27, Issue 5 SUPPL. 10, 2000, Pages 72-77

  Sobrero, A ^a   Guglielmi, A ^a   Grossi, F ^a   Puglisi, F ^a   Aschele, C ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; CAPECITABINE; DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOROURIDINE; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; THYMIDYLATE SYNTHASE INHIBITOR; TRIMETREXATE; UFT;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTINUOUS INFUSION; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FLUOROURACIL; FOLIC ACID ANTAGONISTS; HUMAN; LEUCOVORIN; PRODRUGS; SUPPORT, NON-U.S. GOV'T; TEGAFUR; URACIL;

EID: 0033783056     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Fluorouracil in colorectal cancer: A tale of two drugs. Implications for biochemical modulation
2. 5-Fluoropyrimidines
3. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drag synergism
4. Fluoropyrimidine-induced antagonism to free and tightly bound methotrexate: Suppression of 14C formate incorporation into RNA and protein
5. Effect of methotrexate and 5-fluorodeoxyuridine on ribonucleotide reductase activity in mammalian cells
6. 5-Fluorouracil-methotrexate synergy. Enhancement of 5-fluorodeoxyuridine binding to thymidylate synthetase by dihydropteroylpolyglutamates
7. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate
8. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells
9. The effects of methotrexate on levels of dUTP in animal cells
10. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion
11. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue: Correlation of antitumor activity with dosage and FUra incorporation into RNA
12. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells
13. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
14. Synergism and lack of cross-resistance between short term and continuous exposure to fluorouracil in human colon adenocarcinoma cells
15. A prospectively randomized trial comparing 5FU bolus with low dose folinic acid (FUFOLld) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer
16. Schedule-selective biochemical modulation of 5-fluorouracil: A phase II study in advanced colorectal cancer
17. Schedule selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A multicentric phase II study
18. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma
19. Activation and cytotoxicity of 5'-deoxy-5-fluorouridine in c-Ha-ras transfected NIH 3T3 cells
20. Tissue distribution of 5'-deoxy-5-fluorouridine and deliver 5-fluorouracil in tumor bearing mice and rats
21. Pharmacokinetics and pharmacodynamics of capecitabine in two phase I studies
22. Clinical pharmacology of 5-fluorouracil
23. 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma
24. Pharmacokinetic, oral bioavailability and safety study of 5-fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase
25. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal cancer
26. S1, new oral fluoropyrimidine is very active in patients with advanced gastric cancer